CTOs on the Move

Intermountain Medical Solutions

www.imsut.com

 
Intermountain Medical Solutions is a Heber City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.imsut.com
  • 742 W 100 S
    Heber City, UT USA 84032
  • Phone: 801.971.4900

Executives

Name Title Contact Details

Similar Companies

av ox inc

av ox inc is a Van Nuys, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Revolution Enterprises

Revolution Cannabis is committed to producing the cleanest, most reliable and efficacious medical cannabis products. Our team is comprised of passionate cannabis cultivation, public health, and research professionals united by a desire to cultivate health and happiness through the science of cannabis. Revolution`s core values permeate every facet of operations spanning cultivation, breeding, production, packaging, labeling, community outreach, and more.

OBS Medical

OBS Medical is a Carmel, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ARMUS Corporation

ARMUS Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

LumiThera

At LumiThera, we are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. We will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company`s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area. The Valeda Light Delivery System is CE Marked. The device is not for sale in the USA.